🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 14 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
15/09/2021 33,31 34,06 32,47 33,37 +1,09% 4,76% 369.500
14/09/2021 33,52 33,80 32,38 33,01 -2,57% 4,24% 464.900
13/09/2021 32,31 34,44 31,08 33,88 +4,60% 10,40% 594.400
10/09/2021 34,64 34,64 31,00 32,39 -5,93% 10,51% 753.600
09/09/2021 34,25 35,30 33,92 34,43 +0,35% 4,03% 485.700
08/09/2021 33,34 34,36 32,92 34,31 +2,17% 4,32% 270.400
07/09/2021 33,17 33,78 32,40 33,58 +0,48% 4,16% 284.200
03/09/2021 32,86 34,33 32,43 33,42 +0,30% 5,77% 372.500
02/09/2021 31,85 33,39 31,52 33,32 +5,61% 5,87% 522.200
01/09/2021 29,49 31,74 29,26 31,55 +8,16% 8,41% 504.700
31/08/2021 29,57 30,03 28,91 29,17 -1,65% 3,79% 351.400
30/08/2021 29,74 30,84 29,19 29,66 +0,47% 5,55% 388.400
27/08/2021 29,19 30,20 28,78 29,52 +2,22% 4,86% 281.200
26/08/2021 29,13 29,86 28,78 28,88 -1,94% 3,71% 210.900
25/08/2021 29,06 29,60 28,71 29,45 +1,73% 3,06% 200.900
24/08/2021 29,09 29,50 28,03 28,95 -1,36% 5,05% 196.400
23/08/2021 28,39 29,92 28,39 29,35 +3,42% 5,39% 384.200
20/08/2021 26,85 28,47 26,74 28,38 +5,38% 6,44% 325.200
19/08/2021 27,49 27,97 26,85 26,93 -2,57% 4,07% 341.800
18/08/2021 28,52 28,52 27,58 27,64 -2,64% 3,30% 190.400
17/08/2021 26,94 28,46 26,60 28,39 +4,76% 6,90% 311.700
16/08/2021 27,06 27,59 26,78 27,10 -0,99% 2,99% 310.300
13/08/2021 28,01 28,19 27,30 27,37 -1,48% 3,18% 190.000
12/08/2021 27,19 27,84 27,00 27,78 +1,24% 3,09% 445.200
11/08/2021 28,46 28,46 26,94 27,44 -4,26% 5,34% 439.000
10/08/2021 28,59 28,71 28,20 28,66 +1,49% 1,78% 379.800
09/08/2021 27,16 28,76 27,00 28,24 +3,60% 6,47% 585.500
06/08/2021 30,52 31,49 27,00 27,26 -10,56% 14,71% 930.500
05/08/2021 29,36 30,77 29,18 30,48 +3,67% 5,42% 377.700
04/08/2021 29,82 30,48 29,24 29,40 -2,07% 4,16% 315.800